Arlene Siefker-Radtke is Professor of Genitourinary Medical Oncology at the University of Texas, MD Anderson Cancer Center, Houston, TX, USA, and is Clinical Co-Leader of the MD Anderson Bladder Specialized Program of Research Excellence (SPORE).
Prof. Siefker-Radtke’s research focus is on developing effective therapies for the treatment of urothelial cancer and other rare tumours of the bladder and upper tract. She is well known for her novel clinical trial designs; development of novel agents and targets including immunotherapy, fibroblast growth factor receptor inhibitors, and proteasome inhibitors; development of neoadjuvant chemotherapy; and expertise in treating even the most rare tumours of the bladder.
Prof. Siefker-Radtke is a prolific author and a member of the NIH Bladder Cancer Task Force.
EM-09612 - Date of preparation: April 2019